A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Public ClinicalTrials.gov record NCT06950034. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients With Advanced Hematologic Malignancies
Study identification
- NCT ID
- NCT06950034
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Solu Therapeutics, Inc
- Industry
- Enrollment
- 105 participants
Conditions and interventions
Conditions
- Acute Monocytic Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia Post Cytotoxic Therapy
- Acute Myeloid Leukemias
- CMML
- Chronic Myelomonocytic Leukemia
- Chronic Myelomonocytic Leukemia (CMML)
- Chronic Myelomonocytic Leukemia-1
- Chronic Myelomonocytic Leukemia-2
- Refractory Acute Myeloid Leukemia (AML)
- Refractory Chronic Myelomonocytic Leukemia
Interventions
- STX-0712 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 12, 2025
- Primary completion
- Dec 30, 2026
- Completion
- Jun 29, 2027
- Last update posted
- Feb 8, 2026
2025 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Stanford | California | 94305 | Recruiting |
| Moffitt | Tampa | Florida | 12902 | Recruiting |
| DFCI | Boston | Massachusetts | 02215 | Recruiting |
| Mayo Clinic | Rochester | Minnesota | 55905 | Recruiting |
| OHSU | Portland | Oregon | 97239 | Recruiting |
| Vanderbilt University | Nashville | Tennessee | 37232 | Not yet recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06950034, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06950034 live on ClinicalTrials.gov.